BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET

Company Participants

Bruce Mackle - LifeSci Advisors, Investor Relations
Jay Short - Chairman, Chief Executive Officer and Cofounder
Richard Waldron - Chief Financial Officer
Eric Sievers - Chief Medical Officer

Conference Call Participants

Jeet Mukherjee - BTIG
Tony Butler - Rodman & Renshaw
Yu He - H.C. Wainwright

Operator

Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call. [Operator Instructions] It is now my pleasure to turn the conference over to Bruce Mackle with LifeSci Advisors.

Bruce Mackle

Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; and Richard Waldron, Chief Financial Officer. Following today's call, Dr. Eric Sievers, Chief Medical Officer; and Sherry Ledek, Chief Commercial Officer, will join Jay and Rick in a short Q&A. Earlier this afternoon, BioAtla released financial results and a business update for the third quarter ended September 30, 2024. A copy of the press release and corporate presentation are available on the company's website.

Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla's business plans and prospects and whether it's clinical trials will support registration, plans to form collaborations and other strategic partnerships for selected assets achievement of milestones, results, conduct, progress and timing of its research and development programs and clinical trials; expectations with respect to enrollment and dosing in its clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions, the potential regulatory approval path for its product candidates expectations about the sufficiency of its cash and cash equivalents to fund operations and expectations regarding R&D expenses and cash burn. These statements are subject to various risks, assumptions and uncertainties